Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
|Articles|September 5, 2018
HBA and Healthcare Companies Partner in Gender Parity Collaborative
Advertisement
The Healthcare Businesswomen’s Association (HBA) announced that 12 healthcare and life science companies have started a partnership to advance gender parity progress in the industry. The founding member companies serve as role models with all 12 organizations supporting internal women’s leadership networks and more than half recognized by national business media outlets for progressive diversity and inclusion programs, along with representing a work force of more than 750,000 employees collectively globally.
While similar corporate partnerships exist, the HBA’s Collaborative is different in that all member companies are in the healthcare and life science business. The twelve founding member companies are Advanced Clinical, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, GlaxoSmithKline, Medidata Solutions, Novartis, Pfizer, Quest Diagnostics, Genentech, a member of the Roche group, and Sanofi.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5